Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $26.1250.
A number of equities analysts have weighed in on the company. Wall Street Zen downgraded Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Guggenheim lifted their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, June 25th. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. Citigroup increased their target price on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th.
View Our Latest Research Report on Amylyx Pharmaceuticals
Insider Buying and Selling
Institutional Trading of Amylyx Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Meeder Asset Management Inc. bought a new stake in Amylyx Pharmaceuticals during the fourth quarter worth about $25,000. KBC Group NV acquired a new position in Amylyx Pharmaceuticals during the first quarter valued at approximately $26,000. California State Teachers Retirement System bought a new position in Amylyx Pharmaceuticals in the second quarter valued at approximately $28,000. State of Wyoming bought a new position in Amylyx Pharmaceuticals in the second quarter valued at approximately $40,000. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Amylyx Pharmaceuticals by 954.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after purchasing an additional 3,493 shares during the last quarter. Institutional investors and hedge funds own 95.84% of the company’s stock.
Amylyx Pharmaceuticals Price Performance
Shares of Amylyx Pharmaceuticals stock opened at $21.43 on Thursday. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of -14.99 and a beta of -0.21. The stock’s 50-day moving average is $18.44 and its 200-day moving average is $16.04. Amylyx Pharmaceuticals has a one year low of $7.63 and a one year high of $24.60.
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). On average, equities analysts expect that Amylyx Pharmaceuticals will post -1.45 EPS for the current year.
Amylyx Pharmaceuticals Company Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.
Featured Stories
- Five stocks we like better than Amylyx Pharmaceuticals
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
